{"id":30706,"date":"2025-03-27T14:32:46","date_gmt":"2025-03-27T06:32:46","guid":{"rendered":"https:\/\/flcube.com\/?p=30706"},"modified":"2025-03-27T14:32:48","modified_gmt":"2025-03-27T06:32:48","slug":"bayer-inks-licensing-deal-for-suzhou-puhes-prmt5-inhibitor-bay-3713372","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=30706","title":{"rendered":"Bayer Inks Licensing Deal for Suzhou Puhe’s PRMT5 Inhibitor, BAY 3713372"},"content":{"rendered":"\n

German pharmaceutical giant Bayer (ETR: BAYN<\/a>) has entered into a licensing agreement with Suzhou Puhe Biopharma Co., Ltd, acquiring global exclusive development, manufacturing, and commercialization rights to the Chinese firm\u2019s MTA-cooperative PRMT5 inhibitor, designated as BAY 3713372. Financial details of the deal were not disclosed. Bayer has enrolled the first patient in the Phase I dosage escalation study evaluating the drug in MTAP-deficient solid tumors.<\/p>\n\n\n\n

Drug Development and Targeting<\/strong>
BAY 3713372, an investigational drug not yet approved anywhere in the world, is notable for its brain permeability, enabling it to target central nervous system (CNS) metastases and primary brain tumors. This unique feature positions the drug as a potential candidate for addressing unmet medical needs in brain-related malignancies.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

German pharmaceutical giant Bayer (ETR: BAYN) has entered into a licensing agreement with Suzhou Puhe…<\/p>\n","protected":false},"author":1,"featured_media":30708,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[269,16,967,3935],"class_list":["post-30706","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-bayer","tag-cancer","tag-etr-bayn","tag-puhe-biopharma"],"yoast_head":"\nBayer Inks Licensing Deal for Suzhou Puhe's PRMT5 Inhibitor, BAY 3713372 - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"German pharmaceutical giant Bayer (ETR: BAYN) has entered into a licensing agreement with Suzhou Puhe Biopharma Co., Ltd, acquiring global exclusive development, manufacturing, and commercialization rights to the Chinese firm\u2019s MTA-cooperative PRMT5 inhibitor, designated as BAY 3713372. Financial details of the deal were not disclosed. Bayer has enrolled the first patient in the Phase I dosage escalation study evaluating the drug in MTAP-deficient solid tumors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=30706\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bayer Inks Licensing Deal for Suzhou Puhe's PRMT5 Inhibitor, BAY 3713372\" \/>\n<meta property=\"og:description\" content=\"German pharmaceutical giant Bayer (ETR: BAYN) has entered into a licensing agreement with Suzhou Puhe Biopharma Co., Ltd, acquiring global exclusive development, manufacturing, and commercialization rights to the Chinese firm\u2019s MTA-cooperative PRMT5 inhibitor, designated as BAY 3713372. Financial details of the deal were not disclosed. Bayer has enrolled the first patient in the Phase I dosage escalation study evaluating the drug in MTAP-deficient solid tumors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=30706\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-27T06:32:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-27T06:32:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2705-png.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30706#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30706\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bayer Inks Licensing Deal for Suzhou Puhe’s PRMT5 Inhibitor, BAY 3713372\",\"datePublished\":\"2025-03-27T06:32:46+00:00\",\"dateModified\":\"2025-03-27T06:32:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30706\"},\"wordCount\":132,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30706#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2705-png.webp\",\"keywords\":[\"Bayer\",\"Cancer\",\"ETR: BAYN\",\"Puhe Biopharma\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=30706#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30706\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=30706\",\"name\":\"Bayer Inks Licensing Deal for Suzhou Puhe's PRMT5 Inhibitor, BAY 3713372 - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30706#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30706#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2705-png.webp\",\"datePublished\":\"2025-03-27T06:32:46+00:00\",\"dateModified\":\"2025-03-27T06:32:48+00:00\",\"description\":\"German pharmaceutical giant Bayer (ETR: BAYN) has entered into a licensing agreement with Suzhou Puhe Biopharma Co., Ltd, acquiring global exclusive development, manufacturing, and commercialization rights to the Chinese firm\u2019s MTA-cooperative PRMT5 inhibitor, designated as BAY 3713372. Financial details of the deal were not disclosed. Bayer has enrolled the first patient in the Phase I dosage escalation study evaluating the drug in MTAP-deficient solid tumors.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30706#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=30706\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30706#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2705-png.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2705-png.webp\",\"width\":1080,\"height\":608,\"caption\":\"Bayer Inks Licensing Deal for Suzhou Puhe's PRMT5 Inhibitor, BAY 3713372\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30706#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bayer Inks Licensing Deal for Suzhou Puhe’s PRMT5 Inhibitor, BAY 3713372\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bayer Inks Licensing Deal for Suzhou Puhe's PRMT5 Inhibitor, BAY 3713372 - Insight, China's Pharmaceutical Industry","description":"German pharmaceutical giant Bayer (ETR: BAYN) has entered into a licensing agreement with Suzhou Puhe Biopharma Co., Ltd, acquiring global exclusive development, manufacturing, and commercialization rights to the Chinese firm\u2019s MTA-cooperative PRMT5 inhibitor, designated as BAY 3713372. Financial details of the deal were not disclosed. Bayer has enrolled the first patient in the Phase I dosage escalation study evaluating the drug in MTAP-deficient solid tumors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=30706","og_locale":"en_US","og_type":"article","og_title":"Bayer Inks Licensing Deal for Suzhou Puhe's PRMT5 Inhibitor, BAY 3713372","og_description":"German pharmaceutical giant Bayer (ETR: BAYN) has entered into a licensing agreement with Suzhou Puhe Biopharma Co., Ltd, acquiring global exclusive development, manufacturing, and commercialization rights to the Chinese firm\u2019s MTA-cooperative PRMT5 inhibitor, designated as BAY 3713372. Financial details of the deal were not disclosed. Bayer has enrolled the first patient in the Phase I dosage escalation study evaluating the drug in MTAP-deficient solid tumors.","og_url":"https:\/\/flcube.com\/?p=30706","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-03-27T06:32:46+00:00","article_modified_time":"2025-03-27T06:32:48+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2705-png.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=30706#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=30706"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bayer Inks Licensing Deal for Suzhou Puhe’s PRMT5 Inhibitor, BAY 3713372","datePublished":"2025-03-27T06:32:46+00:00","dateModified":"2025-03-27T06:32:48+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=30706"},"wordCount":132,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=30706#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2705-png.webp","keywords":["Bayer","Cancer","ETR: BAYN","Puhe Biopharma"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=30706#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=30706","url":"https:\/\/flcube.com\/?p=30706","name":"Bayer Inks Licensing Deal for Suzhou Puhe's PRMT5 Inhibitor, BAY 3713372 - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=30706#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=30706#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2705-png.webp","datePublished":"2025-03-27T06:32:46+00:00","dateModified":"2025-03-27T06:32:48+00:00","description":"German pharmaceutical giant Bayer (ETR: BAYN) has entered into a licensing agreement with Suzhou Puhe Biopharma Co., Ltd, acquiring global exclusive development, manufacturing, and commercialization rights to the Chinese firm\u2019s MTA-cooperative PRMT5 inhibitor, designated as BAY 3713372. Financial details of the deal were not disclosed. Bayer has enrolled the first patient in the Phase I dosage escalation study evaluating the drug in MTAP-deficient solid tumors.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=30706#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=30706"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=30706#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2705-png.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2705-png.webp","width":1080,"height":608,"caption":"Bayer Inks Licensing Deal for Suzhou Puhe's PRMT5 Inhibitor, BAY 3713372"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=30706#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bayer Inks Licensing Deal for Suzhou Puhe’s PRMT5 Inhibitor, BAY 3713372"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2705-png.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30706","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=30706"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30706\/revisions"}],"predecessor-version":[{"id":30709,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30706\/revisions\/30709"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/30708"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=30706"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=30706"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=30706"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}